PMC10363977_01
(A-C) Panel of radiological imaging concerning basal condition (June 2020) and presence of lung metastases. (D-F) Panel of radiological imaging concerning response to treatment (September 2020).
fonc-13-1145986-g001.jpg
PMC10363977_01_fonc-13-1145986-g001.jpg
f1
Three months later (September 2020), a CT scan evaluation showed partial response with 80% reduction of lung metastases ( Figures 1A-F ) and appearance of some cavitations ( Figures 2A, B ).
(A, B) Radiological evidence of "air-filled" cavitation.
fonc-13-1145986-g002.jpg
PMC10363977_01_fonc-13-1145986-g002.jpg
f2
Three months later (September 2020), a CT scan evaluation showed partial response with 80% reduction of lung metastases ( Figures 1A-F ) and appearance of some cavitations ( Figures 2A, B ).
Clinical trend of biochemical markers (CA 125, CA 15.3, and HE4) and hematological inflammatory marker (NLR) according to response to treatment and "stop and go" strategy.
fonc-13-1145986-g003.jpg
PMC10363977_01_fonc-13-1145986-g003.jpg
f3
Treatment and history timeline.
fonc-13-1145986-g004.jpg
PMC10363977_01_fonc-13-1145986-g004.jpg
f4